SJS Investment Consulting’s NovoCure NVCR Stock Holding History

SJS Investment Consulting’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22.9K	Sell	2,102 -1,080	-34%	-$13.5K	﹤0.01%	634
2025 Q4	$41.1K	Buy	3,182 +22	+0.7%	+$282	0.01%	418
2025 Q3	$40.8K	Buy	+3,160	New	+$42.2K	0.01%	392
2024 Q1	–	Sell	-12	Closed	-$180	–	1676
2023 Q4	$180	Hold	12	–	–	﹤0.01%	1480
2023 Q3	$194	Hold	12	–	–	﹤0.01%	1462
2023 Q2	$498	Hold	12	–	–	﹤0.01%	1171
2023 Q1	$722	Hold	12	–	–	﹤0.01%	1014
2022 Q4	$880	Hold	12	–	–	﹤0.01%	1000
2022 Q3	$1K	Buy	+12	New	+$936	﹤0.01%	841
2022 Q1	$1K	Buy	+12	New	+$884	﹤0.01%	610

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

SJS Investment Consulting's NVCR Position: Q1 2026 in Review

SJS Investment Consulting reduced its NovoCure (NVCR) stake by 34% in Q1 2026, selling an estimated $13.5K and leaving 2,102 shares worth $22.9K. The position accounts for ﹤0.01% of the portfolio, ranked #634.

SJS Investment Consulting first reported a position in NVCR in Q1 2022 and has held it in 10 quarters since. The position peaked at $41.1K in Q4 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

SJS Investment Consulting held 2,102 shares of NovoCure worth $22.9K as of Q1 2026.
SJS Investment Consulting sold 1,080 NovoCure shares in Q1 2026, an estimated $13.5K.
NovoCure made up ﹤0.01% of SJS Investment Consulting's portfolio in Q1 2026, its #634 holding.
SJS Investment Consulting first reported a position in NovoCure in Q1 2022 and has held it in 10 quarters since.
SJS Investment Consulting's NovoCure position peaked at $41.1K in Q4 2025.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on SJS Investment Consulting's 13F filing for Q1 2026, filed 23 Apr 2026.